Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response. We thus examined whether the response to first line chemother...

Full description

Bibliographic Details
Main Authors: Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:OncoImmunology
Subjects:
first-line chemotherapy
nivolumab
non-small-cell lung cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1339856

Internet

http://dx.doi.org/10.1080/2162402X.2017.1339856

Similar Items